Figure 1 | Scientific Reports

Figure 1

From: PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma

Figure 1

Overall survival (OS) and progression-free survival (PFS) of Tmab-combined chemotherapy (Tmab-CTx). (a) OS was calculated from the date when Tmab-based therapy was first administered. (b) PFS was defined as the period from the date when Tmab-CTx was first administered to the date when an objective evaluation as “progression” was determined from the review of the patient chart or to patient’s death. Survival curves were obtained using the Kaplan–Meier method and analyzed using the log-rank test.

Back to article page